U.S. FDA Approves Eisai Oral Aloxi For Preventing CINV

This article was originally published in PharmAsia News

25 Aug 2008
News

PharmAsia News @PharmAsiaNews pharmasia@informa.com

Executive Summary

TOKYO - Eisai said Aug. 24 that it had obtained U.S. FDA approval for an oral capsule formulation of Aloxi (palonosetron) for preventing chemotherapy-induced nausea and voting, broadening the company's reach into the CINV market

Already Registered? Sign in to continue reading.

New to Scrip? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

SC069381

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

SC069381

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

U.S. FDA Approves Eisai Oral Aloxi For Preventing CINV

News

Executive Summary

Related Content

Eisai Wins U.S. FDA Post-Operative Indication For Antiemetic Aloxi

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

Eisai Strengthens Oncology Position With $3.9 Billion MGI Pharma Acquisition

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert